¼¼°èÀÇ Àڱó» À̺ÐôÃß ½ÃÀå º¸°í¼­(2025³â)
Spina Bifida In-Utero Global Market Report 2025
»óǰÄÚµå : 1731042
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Àڱó» À̺ÐôÃß ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. ¿¹»ó ¼ºÀå·üÀº ÀӽŠÁß Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Çâ»ó, ÃÖ¼Ò Ä§½ÀÀû ¼ö¼ú ¹æ¹ýÀÇ È®»ê, Á¤ºÎ Áö¿ø ¹× ÀÚ±Ý ÅõÀÔ Áõ°¡, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®Àå, Àü¹® ÅÂ¾Æ ¼ö¼ú ¼¾ÅÍÀÇ Áõ°¡ µî¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ ±â°£ÀÇ ÁÖ¿ä Æ®·»µå¿¡´Â ÀӽŠÁß ¼±º° °Ë»ç ¹× Áø´Ü ±â¼úÀÇ ¹ßÀü, ÃÖ¼Ò Ä§½ÀÀû ¼ö¼ú ±â¼úÀÇ ±â¼ú Çõ½Å, ÅÂ¾Æ ¼ö¼ú¿ë »ýü Àç·á °³¹ß, ¾ç¼ö ±â¹Ý Ä¡·á¹ý Çõ½Å, ÅÂ¾Æ ¹ß´Þ Áö¿øÀ» À§ÇÑ Àΰø Àڱà ±â¼ú äÅà µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÇ·á ½Ã¼³ÀÇ È®ÀåÀº À̺ÐôÃß ÅÂ¾Æ ½ÃÀå È®´ë¸¦ ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á ½Ã¼³Àº È¿°úÀûÀÎ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ ÇÊ¿äÇÑ Çʼö ÀÎÇÁ¶ó, ½Ã½ºÅÛ, ÀÚ¿øÀ» ÀǹÌÇÕ´Ï´Ù. ÀÇ·á ÀÎÇÁ¶óÀÇ È®ÀåÀº ÁÖ·Î ¿ø°ÝÀÇ·á, ·Îº¿ ¼ö¼ú, AI ±â¹Ý Áø´Ü µî ÀÇ·á ±â¼úÀÇ ¹ßÀü¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úµéÀº ȯÀÚ °á°ú¿Í È¿À²¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ÃֽŠ½Ã¼³, Àü¹® Àåºñ, °³¼±µÈ ÀÇ·á Á¦°ø ½Ã½ºÅÛÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·á ½Ã¼³Àº Áõ°Å ±â¹Ý Ä¡·á¹ý, ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡, Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Á¢±ÙÀ» º¸ÀåÇÔÀ¸·Î½á À̺ÐôÃß ÅÂ¾Æ Ä¡·á¸¦ Áö¿øÇϸç, À̴ ȯÀÚÀÇ Ä¡À¯ °á°ú¿Í »îÀÇ ÁúÀ» °³¼±ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹¿¡ º»»ç¸¦ µÎ°í ÀÖ´Â ºñ¿µ¸® ´ÜüÀÎ ¹Ì±¹ º´¿ø Çùȸ(American Hospital Association)´Â 2024³â ¹Ì±¹ ³» º´¿ø ¼ö°¡ 2022³âÀÇ 6,093°³¿¡¼­ 6,120°³·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù.

Àڱó» À̺ÐôÃß ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷Àº ÷´Ü ¿µ»ó ±â¼ú°ú ÃÖ¼Ò Ä§½ÀÀû ±â¼úÀ» °áÇÕÇÑ ¼ö¼ú ¼¾ÅÍ µî Çõ½ÅÀûÀÎ ¼¾ÅÍ ¼³¸³¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¼ö¼ú ¼¾ÅÍ´Â ÀÔ¿ø ¾øÀÌ ¿Ü·¡ ȯÀÚ ´ë»óÀ¸·Î ¼ö¼úÀ» ¼öÇàÇÏ´Â Àü¹® ½Ã¼³·Î, º´¿ø ÀÔ¿ø Çʿ伺À» Á¦°ÅÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 1¿ù Àεµ¿¡ À§Ä¡ÇÑ ¿Íµð¾Æ º´¿øÀº °³¹æ¼º À̺ÐôÃß¿¡ ´ëÇÑ ÅÂ¾Æ ¼ö¼úÀ» Á¦°øÇÏ´Â ¼¾Å͸¦ °³¼ÒÇß½À´Ï´Ù. ÀÌ ½Ã¼³Àº Ãֽмö¼ú ±â¼ú°ú ´ÙÇÐÁ¦Àû Á¢±Ù ¹æ½ÄÀ» ÅëÇÕÇØ Á¶±â °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϸç, ÀÌ´Â ÇØ´ç ÁúȯÀ¸·Î °íÅë¹Þ´Â ¿µ¾ÆÀÇ ÇÕº´ÁõÀ» ÁÙÀ̰í Àå±âÀû ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¼¾ÅÍ´Â ¼ö¼úÀÇ Á¤¹Ð¼º°ú °íǰÁú ȯÀÚ °ü¸®¸¦ °­Á¶Çϸç, °³¹æ¼º À̺ÐôÃßÀ¸·Î ¾î·Á¿òÀ» °Þ´Â °¡Á·µé¿¡°Ô Èñ¸ÁÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Spina bifida in-utero refers to a prenatal surgical procedure aimed at repairing spina bifida, a neural tube defect in which the spine and spinal cord fail to develop properly. Performed before birth, this surgery helps reduce complications such as hydrocephalus, enhances mobility, and improves neurological outcomes. By closing the defect early, it protects the exposed spinal cord from further damage, ultimately improving the child's quality of life compared to postnatal repair.

The primary types of spina bifida in-utero include myelomeningocele, meningocele, and occulta. Myelomeningocele is the most severe form, characterized by the protrusion of the spinal cord and meninges through an opening in the spine. Diagnosis methods include ultrasound, magnetic resonance imaging (MRI), and amniocentesis. Treatment options consist of in-utero surgery, postnatal surgery, and medication management. These interventions are utilized in various healthcare settings, including hospitals, specialty clinics, and ambulatory surgical centers.

The spina bifida in-utero market research report is one of a series of new reports from The Business Research Company that provides spina bifida in-utero market statistics, including spina bifida in-utero industry global market size, regional shares, competitors with a spina bifida in-utero market share, detailed spina bifida in-utero market segments, market trends and opportunities, and any further data you may need to thrive in the spina bifida in-utero industry. This spina bifida in-utero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The spina bifida in utero market size has grown strongly in recent years. It will grow from $2.42 billion in 2024 to $2.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth during the historic period can be attributed to the rising prevalence of spina bifida, increased awareness of fetal surgery, higher maternal age and associated pregnancy risks, growing healthcare expenditures, and advancements in research and development within fetal medicine.

The spina bifida in utero market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The projected growth during the forecast period can be attributed to rising awareness of prenatal diagnosis and treatment, greater adoption of minimally invasive procedures, increased government initiatives and funding, the expansion of healthcare infrastructure in emerging markets, and the growing number of specialized fetal surgery centers. Key trends for this period include advancements in prenatal screening and diagnostics, technological innovations in minimally invasive surgical techniques, the development of biomaterials for fetal surgery, innovations in amniotic fluid-based therapies, and the adoption of artificial womb technology to support fetal development.

The growth of healthcare facilities is expected to drive the expansion of the spina bifida in-utero market. Healthcare facilities refer to the essential infrastructure, systems, and resources required to provide effective medical services. The expansion of healthcare infrastructure is primarily attributed to advancements in medical technology, such as telemedicine, robotic surgery, and AI-driven diagnostics, all of which require updated facilities, specialized equipment, and improved healthcare delivery systems to enhance patient outcomes and efficiency. These healthcare facilities support spina bifida in-utero by ensuring access to evidence-based therapies, skilled medical professionals, and innovative treatment options, all of which improve healing outcomes and quality of life for patients. For example, the American Hospital Association, a US-based non-profit organization, reported that the total number of hospitals in the United States reached 6,120 in 2024, a rise from 6,093 hospitals in 2022. This growth in healthcare infrastructure is thus contributing to the development of the spina bifida in-utero market.

Companies operating in the spina bifida in-utero market are focusing on establishing innovative centers, such as surgery centers, that incorporate advanced imaging and minimally invasive techniques for fetal interventions. Surgery centers are specialized facilities where surgical procedures are performed on an outpatient basis, eliminating the need for hospital admission. For instance, in January 2025, Wadia Hospital, located in India, opened a center offering fetal surgery for open spina bifida. The facility integrates state-of-the-art surgical techniques and a multidisciplinary approach to enable early intervention, which can reduce complications and improve long-term outcomes for infants affected by the condition. The center emphasizes surgical precision and high-quality patient care, offering hope for families dealing with the challenges of open spina bifida.

In March 2024, Lilavati Hospital, an India-based multi-specialty healthcare institution, formed a partnership with the Medical University of Silesia. This collaboration aims to establish a fetal surgery department to provide advanced in-utero treatment for birth defects, including spina bifida. The Medical University of Silesia, located in Poland, is known for its expertise in fetal surgery techniques and in-utero treatments for various conditions.

Major players in the spina bifida in-utero market are Mayo Clinic, GE HealthCare, UC San Francisco, Children's Health, Memorial Hermann Health System, Oregon Health & Science University, Seattle Children's, Texas Children's, Children's Hospital of Philadelphia, UW Health, UC Davis, UCSF Health, Burjeel Hospital, UT Physicians, Thieme Group, Riley Children's Health, Yale Medicine, Focused Ultrasound Foundation, Petals Health, Brown University Health.

North America was the largest region in the spina bifida in utero market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spina bifida in-utero report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the spina bifida in-utero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The spina bifida in-utero market consists of revenues earned by entities providing services such as physical therapy planning, genetic counseling, and multidisciplinary team support. The market value includes the value of related goods sold by the service provider or included within the service offering. The spina bifida in-utero market also includes sales of sales of anesthesia and maternal support equipment, fetal monitoring devices, and biodegradable adhesives and sealants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Spina Bifida In-Utero Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on spina bifida in-utero market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for spina bifida in-utero ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The spina bifida in-utero market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Spina Bifida In-Utero Market Characteristics

3. Spina Bifida In-Utero Market Trends And Strategies

4. Spina Bifida In-Utero Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Spina Bifida In-Utero Growth Analysis And Strategic Analysis Framework

6. Spina Bifida In-Utero Market Segmentation

7. Spina Bifida In-Utero Market Regional And Country Analysis

8. Asia-Pacific Spina Bifida In-Utero Market

9. China Spina Bifida In-Utero Market

10. India Spina Bifida In-Utero Market

11. Japan Spina Bifida In-Utero Market

12. Australia Spina Bifida In-Utero Market

13. Indonesia Spina Bifida In-Utero Market

14. South Korea Spina Bifida In-Utero Market

15. Western Europe Spina Bifida In-Utero Market

16. UK Spina Bifida In-Utero Market

17. Germany Spina Bifida In-Utero Market

18. France Spina Bifida In-Utero Market

19. Italy Spina Bifida In-Utero Market

20. Spain Spina Bifida In-Utero Market

21. Eastern Europe Spina Bifida In-Utero Market

22. Russia Spina Bifida In-Utero Market

23. North America Spina Bifida In-Utero Market

24. USA Spina Bifida In-Utero Market

25. Canada Spina Bifida In-Utero Market

26. South America Spina Bifida In-Utero Market

27. Brazil Spina Bifida In-Utero Market

28. Middle East Spina Bifida In-Utero Market

29. Africa Spina Bifida In-Utero Market

30. Spina Bifida In-Utero Market Competitive Landscape And Company Profiles

31. Spina Bifida In-Utero Market Other Major And Innovative Companies

32. Global Spina Bifida In-Utero Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Spina Bifida In-Utero Market

34. Recent Developments In The Spina Bifida In-Utero Market

35. Spina Bifida In-Utero Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â